Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Eliminating HIV-1 reservoirs.

Roger J Pomerantz1

  • 1Thomas Jefferson University, Philadelphia, PA 19107, USA. roger.j.pomerantz@mail.tju.edu

Current Opinion in Investigational Drugs (London, England : 2000)
|September 5, 2002
PubMed
Summary

Highly active antiretroviral therapy (HAART) effectively treats HIV-1 but does not cure it. Researchers are developing strategies to target latent HIV-1 reservoirs and persistent viral replication.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Phase 1b Safety Study of SER-287, a Spore-Based Microbiome Therapeutic, for Active Mild to Moderate Ulcerative Colitis.

Gastroenterology·2020
Same author

SER-109, an Investigational Microbiome Drug to Reduce Recurrence After Clostridioides difficile Infection: Lessons Learned From a Phase 2 Trial.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2020
Same author

Reply to Lagier et al.

The Journal of infectious diseases·2017
Same author

A Novel Microbiome Therapeutic Increases Gut Microbial Diversity and Prevents Recurrent Clostridium difficile Infection.

The Journal of infectious diseases·2016
Same author

Generation of retroviral particles for the spleen necrosis virus (SNV)-based vector system and their use in transduction of various cell types.

Cold Spring Harbor protocols·2010
Same author

Combined effects of hyperglycemic conditions and HIV-1 Nef: a potential model for induced HIV neuropathogenesis.

Virology journal·2009

Area of Science:

  • Virology
  • Immunology
  • Molecular Pathogenesis

Background:

  • Highly active antiretroviral therapy (HAART) has significantly improved outcomes for many HIV-1 patients.
  • However, HAART does not eliminate HIV-1, with residual disease persisting due to latent proviruses.
  • Low-level, persistent viral replication also occurs during HAART, contributing to disease maintenance.

Purpose of the Study:

  • To explore strategies for targeting cellular reservoirs of HIV-1 persistence.
  • To understand the molecular mechanisms driving HIV-1 latency and residual replication.

Main Methods:

  • Investigating the role of resting CD4+ T-lymphocytes in maintaining HIV-1 reservoirs.
  • Examining the contribution of monocytes/macrophages to HIV-1 persistence.
  • Developing novel therapeutic approaches to activate latent viral reservoirs.
  • Exploring methods to deplete residual viral replication during HAART.

Main Results:

  • Identification of resting CD4+ T-lymphocytes as a key reservoir for persistent HIV-1.
  • Evidence suggesting monocytes/macrophages also harbor latent HIV-1.
  • Development of therapeutic strategies aimed at reservoir activation and viral depletion.
  • Understanding the molecular pathogenesis of HIV-1 persistence.

Conclusions:

  • Targeting cellular reservoirs is crucial for achieving a cure for HIV-1 infection.
  • Activating latent HIV-1 reservoirs and depleting residual replication are key therapeutic goals.
  • Further research into the molecular pathogenesis of HIV-1 is essential for developing effective eradication strategies.

Related Experiment Videos